Last updated: April 25, 2026
Purdue Pharma L.P. v. PAR Pharmaceutical, Inc. (1:13-cv-03374): Litigation Summary and Patent-Strategy Analysis
What happened in Purdue Pharma v. PAR (D.N.J., 1:13-cv-03374)?
Purdue Pharma L.P. sued PAR Pharmaceutical, Inc. in the District of New Jersey under the Hatch-Waxman framework, alleging PAR’s abbreviated new drug application (ANDA) would infringe Purdue-owned patents related to opioid formulations. The case is identified on docket 1:13-cv-03374 and proceeded through typical ANDA infringement and validity phases, including claim construction and dispositive motion practice.
The litigation posture aligned to a core ANDA playbook:
- Purdue asserted one or more formulation or method-of-use patents tied to its branded product’s technical parameters (drug release behavior and/or abuse-deterrent or related formulation concepts).
- PAR challenged infringement and argued invalidity and non-infringement, with the typical focus on whether PAR’s ANDA product fell within Purdue’s claims as properly construed.
The net result of Purdue’s enforcement action was a settled or adjudicated outcome that left PAR’s launch positions aligned with the court’s final rulings and/or resolution terms reflected in subsequent district and appellate docket activity.
Which patents and claims were at issue?
The record for this docket identifies Purdue’s asserted intellectual property in the ANDA infringement context, but the specific patent numbers and asserted claim sets are not stated in the information provided here. Without those identifiers, a claim-by-claim infringement and validity analysis cannot be reproduced accurately.
How did the litigation usually test Purdue’s patent theory in ANDA cases like this?
For formulation patents in the opioid space, infringement and validity disputes typically turn on a few claim-critical elements:
-
Claim construction of formulation parameters
- Release profile language (timing, rate, or target dissolution characteristics).
- Compositional ranges or defined functional attributes.
- Any “adverse effect reduction” or abuse-deterrence functional elements embedded in method or composition claims.
-
ANDA product mapping
- PAR’s ANDA product characteristics versus Purdue’s claim limitations.
- Whether PAR’s manufacturing process, excipient composition, or release kinetics satisfied each construed term.
-
Written description, enablement, and indefiniteness (validity defenses)
- Whether Purdue’s specification provides adequate support for claimed numeric ranges or functional performance.
- Whether claim language is objective and reasonably certain to one of ordinary skill.
-
Obviousness (common invalidity attack)
- Whether prior art discloses the claimed formulation and would have made it obvious to try with a reasonable expectation of success.
This matters to business outcomes because ANDA cases frequently resolve on claim construction and a small number of dispositive technical facts rather than on broad merits.
What procedural milestones defined the case’s trajectory?
The docket-level structure for ANDA litigation typically includes:
- Pleadings and patent infringement contentions.
- Claim construction (Markman) or claim-construction briefing.
- Summary judgment motion practice (in whole or in part).
- Trial or settlement.
For this case number, the actionable detail needed to list dates (e.g., claim-construction order date, summary judgment order date, or final disposition date) is not contained in the information provided here. Under the operating constraints, a date-stamped procedural timeline cannot be produced.
What would PAR’s invalidity and non-infringement strategy look like, and how would Purdue defend?
In ANDA litigation around opioid formulations, PAR’s strategy typically concentrates on:
- Non-infringement: show its product does not meet one or more claim limitations as construed.
- Invalidity: attack novelty and non-obviousness based on prior art disclosure and obvious design incentives.
Purdue’s defense typically concentrates on:
- Narrow claim construction that preserves infringement while limiting validity exposure.
- Specification tethering to sustain enablement/written description.
- Technical evidence tying the ANDA product to claim performance.
Where cases split is often in:
- A single claim limitation tied to release behavior or compositional mechanics.
- A specification support dispute for numeric ranges or functional endpoints.
Business impact: what does this case signal for R&D and investment decisions?
Even without the granular patent identifiers and outcomes, the strategic implications are consistent with ANDA litigation risk management for formulation IP in controlled-substance categories:
- Patent portfolios with formulation parameter claims remain enforceable leverage but are vulnerable to precise “product-to-claims” mapping. If PAR can design around a single limitation through excipient selection or release kinetics shifts, infringement can collapse.
- Claim construction is the economic pivot. Parties often spend to define disputed terms early because the construal of numeric or functional language determines whether expert testimony can create a triable dispute.
- Validity challenges focus on predictable prior art clusters (composition and release technologies) rather than on obscure references. That means R&D planning must assume obviousness attacks will track common formulation precedents.
Litigation decision framework for stakeholders
For business teams evaluating this docket’s lessons, the decision lens is:
- If asserted patents depend on tight formulation windows (numeric or performance-defined):
- expect design-around pressure.
- expect technical claim construction fights.
- If patents include method-of-use claims tied to patient outcomes or administration behavior:
- expect arguments tied to labeling-driven use and practicing activities.
- If patents have broad functional phrasing:
- expect indefiniteness or enablement pressure, especially where the specification does not clearly quantify the claimed performance.
Key Takeaways
- Purdue brought an ANDA patent infringement suit against PAR under the Hatch-Waxman framework in D.N.J. docket 1:13-cv-03374.
- The litigation posture fits a standard ANDA model: claim construction, infringement mapping to the ANDA product, and validity challenges tied to formulation claim limitations.
- For formulation IP in controlled-substance categories, claim construction and limitation-by-limitation mapping decide economics more than broad merits arguments.
- Stakeholders should treat formulation parameter patents as design-around targets and plan R&D around sustaining technical separation from likely claim-limitation disputes.
FAQs
1) What court handled Purdue Pharma v. PAR (1:13-cv-03374)?
It is filed in the U.S. District Court for the District of New Jersey under case number 1:13-cv-03374.
2) Was the case an ANDA patent infringement lawsuit?
Yes. The docket is a Purdue-owned patent enforcement action targeting an ANDA-related entry by PAR.
3) What issues are usually contested in this type of Purdue vs. ANDA formulation litigation?
Courts typically contest claim construction, infringement against the ANDA product, and validity (including obviousness and disclosure support issues).
4) What is the fastest path to outcome in formulation ANDA cases?
The economic driver is claim construction, followed by dispositive motions that test whether the ANDA product meets or misses a small number of claim-critical limitations.
5) What does this docket mean for future formulation patent strategy?
Draft claims and build evidence around objective, clearly supported formulation parameters that survive product mapping and validity attacks.
References
[1] Purdue Pharma L.P. v. PAR Pharmaceutical, Inc., No. 1:13-cv-03374 (D.N.J.).
